CD274 and melanoma: In a large cohort of 405 melanoma patients who were treated with pembrolizumab, Daud et al. [10] showed that the highest response rates (53–57%) were found for PD-L1 positive tumors (corresponding to ≥10% staining), whereas patients with PD-L1 negative tumors (corresponding to <1% staining) showed response rates of 8–12%.